Cancer

Overview

BOT Bioscience's Cancer Series is a specialized reagent portfolio designed for oncology research, diagnostic development, and therapeutic discovery applications. It covers a wide range of cancer-related targets—including tumor-associated antigens, oncogenes, tumor suppressor proteins, cancer biomarkers, and immune checkpoint molecules—supporting applications such as cancer biomarker discovery, immuno-oncology research, antibody-drug conjugate development, and companion diagnostic assay development. The series offers multiple product formats including monoclonal antibodies, recombinant proteins, antibody fragments (Fab, Scfv), and ELISA kits, ensuring high specificity, low cross-reactivity, and reliable performance across diverse experimental platforms. With rigorous quality control and flexible customization options, the Cancer Series provides essential tools to accelerate research in tumor biology, precision medicine, and cancer immunotherapy.

 

Categories and Applications

Product Category

Key Product Examples

Common Application Scenarios

Tumor-Associated Antigen Antibodies


1. Immuno-oncology research: Detection and targeting of tumor-associated antigens for cancer immunotherapy development.
2. Immunohistochemistry: Enabling tissue staining for biomarker localization and pathological analysis of tumor samples.
3. Antibody-drug conjugate development: Providing specific targeting antibodies for ADC therapeutic development.

Cancer Biomarker Recombinant Proteins


1. Assay development: Serving as calibrators and standards for cancer biomarker immunoassays.
2. Antibody screening: Evaluating antibody specificity and affinity during hybridoma screening and monoclonal antibody development.
3. Immunization and vaccine research: Providing immunogens for generating specific antibodies against cancer targets.

Oncogene & Tumor Suppressor Reagents


1. Cancer mechanism research: Investigating the role of oncogenes and tumor suppressors in cell proliferation, apoptosis, and DNA repair.
2. Drug target discovery: Identifying and validating novel therapeutic targets for cancer treatment.
3. Prognostic biomarker studies: Correlating oncogene expression patterns with patient outcomes and treatment responses.

 

To learn more about our products, please search through keywords or contact us via email at info@bot-bioscience.com. We are looking forward to assisting you in finding the most suitable Cancer Series for your research.

 

Products Highlights

High specificity and affinity validated across multiple immunoassay platforms.

Broad reactivity covering human and other species cancer targets.

Multiple formats available including monoclonal antibodies, recombinant proteins, antibody fragments (Fab, Scfv), and ELISA kits.

Rigorous quality control for consistent batch-to-batch performance and reliable assay results.

Multiple labelling options: biotin, APC, PE, FITC, and other fluorophores for multicolour flow cytometry, imaging, and multiplex assays.

Custom conjugation, bulk packaging, and custom assay development services available upon request.